About
Oral small molecules
Areas of Focus
Categories
Small Molecule PharmaceuticalBoston & New England
Clinical Trials (12)
View allTotal Trials
12
As Lead Sponsor
12
As Collaborator
0
Total Enrollment
437
By Phase
PHASE1: 5PHASE3: 2PHASE1/PHASE2: 3PHASE2: 1
By Status
COMPLETED: 6RECRUITING: 2TERMINATED: 2ACTIVE_NOT_RECRUITING: 1WITHDRAWN: 1
Clinical Trials Pipeline12 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06858696Lead Sponsor
A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
PHASE1Recruiting
48 participants
Started: Feb 28, 2025 · Completed: Apr 30, 2026
NCT06914869Lead Sponsor
Drug-Drug Interaction Potential of Mavorixafor
PHASE1Completed
38 participants
Started: Feb 18, 2025 · Completed: May 19, 2025
NCT06056297Lead Sponsor
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
PHASE3Recruiting
150 participants
Started: Jun 6, 2024 · Completed: Aug 31, 2026
NCT04154488Lead Sponsor
A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders
PHASE1/PHASE2Completed
32 participants
Started: Oct 16, 2021 · Completed: Aug 27, 2024
NCT04274738Lead Sponsor
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
PHASE1Completed
16 participants
Started: Apr 30, 2020 · Completed: Oct 31, 2022
Locations (1)
Headquarters
Boston, MA, United States
Map
Loading map...